Adagio Medical Holdings, Inc. is a medical device company developing and placing on the European Union (EU) market ablation technologies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. Its product portfolio consists of three product families: iCLAS atrial ULTC catheter and accessories, vCLAS ventricular ULTC catheter, and Cryopulse atrial PFCA catheter and accessories. All of these catheters share the same ULTC cryoablation console. A standalone PFA console connected to a cryoablation console for PFCA treatment synchronization is used in conjunction with Cryopulse catheter. The iCLAS system is CE-marked with the indication for treatment of paroxysmal atrial fibrillation, persistent atrial fibrillation and atrial flutter. The vCLAS ventricular catheter has been specifically designed for treatment of the ventricular arrhythmia. Its product offerings consist largely of the single use ablation catheters and consoles.
BörsenkürzelADGM
Name des UnternehmensAdagio Medical Holdings Inc
IPO-datumFeb 26, 2021
CEOMr. Todd Usen
Anzahl der mitarbeiter86
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 26
Addresse26051 Merit Circle
StadtLAGUNA HILLS
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl92653
Telefon12122842300
Website
BörsenkürzelADGM
IPO-datumFeb 26, 2021
CEOMr. Todd Usen
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten